Interferon α kinoid induces neutralizing anti-interferon α antibodies that decrease the expression of interferon-induced and B cell activation associated transcripts: analysis of extended follow-up data from the interferon α kinoid phase I/II study.
Objective. IFN α Kinoid (IFN-K) is a therapeutic vaccine composed of IFNα2b coupled to a carrier protein. In a phase I/II placebo-controlled trial, we observed that IFN-K significantly decreases the IFN gene signature in whole blood RNA samples from SLE patients. Here, we analysed extended follow-up...
| Publicado en: | Rheumatology Vol. 55; no. 10; pp. 1901 - 1906 |
|---|---|
| Autores principales: | , , , , , , , , , , , |
| Formato: | pictorial research tables/charts randomized controlled trial Journal Article |
| Publicado: |
Oxford University Press / USA
Oct2016
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=118309601&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 118309601 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 14620324 DN9 jtl: Rheumatology issn: 14620324 maglogo: N pubinfo: dt: Oct2016 vid: 55 iid: 10 pid: 622 pub: Oxford University Press / USA artinfo: ui: 118309601 118309601 118309601 10.1093/rheumatology/kew262 118309601 ppf: 1901 ppct: 5 formats: tig: atl: Interferon α kinoid induces neutralizing anti-interferon α antibodies that decrease the expression of interferon-induced and B cell activation associated transcripts: analysis of extended follow-up data from the interferon α kinoid phase I/II study. aug: au: Ducreux, Julie Houssiau, Frédéric A. Vandepapelière, Pierre Jorgensen, Christian Lazaro, Estibaliz Spertini, François Colaone, Fabien Roucairol, Camille Laborie, Marion Croughs, Thérèse Grouard-Vogel, Géraldine Lauwerys, Bernard R. affil: Institut de Recherche Expérimentale et Clinique, Pôle de pathologies rhumatismales inflammatoires et systémiques, Université catholique de Louvain, Belgium, France sug: subj: Lupus Erythematosus, Systemic Immunology Interferons Immunology Gene Expression B Lymphocytes Human Randomized Controlled Trials Gene Expression Profiling Descriptive Statistics RNA Analysis Adolescence Young Adult Adult Middle Age Multicenter Studies Data Analysis Software Spearman's Rank Correlation Coefficient Kruskal-Wallis Test Funding Source Adolescent: 13-18 years Adult: 19-44 years Middle Aged: 45-64 years ab: Objective. IFN α Kinoid (IFN-K) is a therapeutic vaccine composed of IFNα2b coupled to a carrier protein. In a phase I/II placebo-controlled trial, we observed that IFN-K significantly decreases the IFN gene signature in whole blood RNA samples from SLE patients. Here, we analysed extended follow-up data from IFN-K-treated patients, in order to evaluate persistence of neutralizing anti-IFNα Abs antibodies (Abs), and gene expression profiling. Methods. Serum and whole blood RNA samples were obtained in IFN-K-treated patients included in the follow-up study, in order to determine binding and neutralizing anti-IFNα Ab titres, and perform high-throughput transcriptomic studies. Results. Neutralization studies of 13 IFNα subtypes demonstrated the polyclonal nature of the Ab response induced by IFN-K. Follow-up analyses in six patients confirmed a significant correlation between neutralizing anti-IFNα Ab titres and decrease in IFN scores compared to baseline. These analyses also revealed an inhibitory effect of IFNα blockade on the expression of B cell associated transcripts. Conclusions. IFN-K induces a polyclonal anti-IFNα response that decreases IFN- and B cell-associated transcripts. Trial registration: ClinicalTrials.gov, clinicaltrials.gov, NCT01058343 pubtype: Academic Journal doctype: pictorial research tables/charts randomized controlled trial Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|